Absci (ABSI) Short term Debt (2020 - 2025)

Absci (ABSI) reported Short term Debt of $12.8 million for Q3 2025, little changed sequentially from $12.8 million in Q2 2025.

Absci (ABSI) Short term Debt (2020 - 2025) Analysis & Trends

Absci (ABSI) has 4 years of Short term Debt data on file, last reported at $12.8 million in Q3 2025.

For the quarter ending Q3 2025, Short term Debt changed N/A year-over-year to $12.8 million; the trailing twelve-month figure through Sep 2025 stood at $12.8 million (changed N/A YoY), and the FY2024 full-year result was $12.8 million, changed 0.0% from the prior year.
Short term Debt held at $12.8 million in Q3 2025, from $12.8 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $12.8 million in Q4 2023 to a low of $12.8 million in Q4 2023.
A 3-year average of $12.8 million and a median of $12.8 million in 2023 frame the typical range for Short term Debt.
Peak annual rise in Short term Debt reached 0.0% in 2024, while the deepest fall reached 0.0% in 2024.
Tracing ABSI's Short term Debt over 3 years: stood at $12.8 million in 2023, then changed by 0.0% to $12.8 million in 2024, then changed by 0.0% to $12.8 million in 2025.
Business Quant data shows ABSI's Short term Debt at $12.8 million in Q3 2025, $12.8 million in Q2 2025, and $12.8 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Absci	1.23 Bn	1.11 Bn	-

Download Data